NEW YORK, Jan. 17, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on NXTM, NVRO, PBH, and VAR which can be accessed for free by signing up to www.wallstequities.com/registration. Today, WallStEquities.com covers the Medical Appliances and Equipment space, which primarily offers equipment
Lawrence, Massachusetts headquartered Nxstage Medical Inc.'s shares slightly declined by 0.57%, closing Tuesday's trading session at $24.63. The stock recorded a trading volume of 296,960 shares. The Company's shares are trading 3.61% below their 50-day moving average. Additionally, shares of Nxstage Medical, which develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure, have a Relative Strength Index (RSI) of 42.36. Get the full research report on NXTM for free by clicking below at:
On Tuesday, shares in Redwood City, California-based Nevro Corp. recorded a trading volume of 675,322 shares, which was above their three months average volume of 475,150 shares. The stock rose 1.51%, ending the day at $79.75. The Company's shares have advanced 16.94% in the past month. The stock is trading above its 50-day moving average by 7.12%. Furthermore, shares of Nevro, which focuses on providing products for the patients suffering from chronic pain in the US and internationally, have an RSI of 64.06.
On January 08th, 2018, Nevro announced that it has received FDA approval for its next-generation Senza II Spinal Cord Stimulation System delivering HF10 therapy. The Senza II system offers the superior outcomes and clinical advantages of HF10 therapy through a smaller and more refined footprint, while maintaining the performance and durability of the current Implantable Pulse Generator. NVRO's complimentary research coverage is a few simple steps away at:
Prestige Brands Holdings
Tarrytown, New York headquartered Prestige Brands Holdings Inc.'s stock finished the day 0.22% higher at $44.94 with a total trading volume of 506,451 shares. The stock is trading above their 50-day moving average by 1.79%. Shares of the Company, which through its subsidiaries, markets, sells, manufactures, and distributes over-the-counter healthcare and household cleaning products in North America, Australia, and internationally, have an RSI of 57.15.
On January 08th, 2018, Prestige Brands announced that it will issue its Q3 FY18 earnings release on February 01st, 2018, before the opening of the market. The Company will host a conference call that same morning at 8:30 a.m. ET to discuss the results. A live webcast of the call will be available under the Investor Relations page of the Company's website. Register for your free research report on PBH at:
Varian Medical Systems
Shares in Palo Alto, California-based Varian Medical Systems Inc. ended yesterday's session 0.38% lower at $108.08. The stock recorded a trading volume of 997,501 shares, which was above its three months average volume of 712,290 shares. The Company's shares have advanced 5.24% over the previous three months and 34.59% over the past year. The stock is trading 5.51% above its 200-day moving average. Moreover, shares of the Company, which designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide, have an RSI of 39.27.
On January 03rd, 2018, research firm Evercore ISI initiated an 'Underperform' rating on the Company's stock.
On January 08th, 2018, Varian Medical Systems announced that its HalcyonTM system has received Taiwan FDA approval, which allows the Company to market this new cancer treatment system in Taiwan. This approval further expands the global availability of Halcyon and high-quality, cost-effective cancer treatments. Wall St. Equities' downloadable research report on VAR available at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/this-mornings-technical-outlook-on-medical-equipment-stocks----nxstage-medical-nevro-prestige-brands-and-varian-medical-systems-300583797.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Exfoliative dermatitis or erythroderma is a skin condition where the skin becomes reddened and ...
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...View All